血清FOXO1、Beclin-1水平与利妥昔单抗治疗初诊弥漫大B细胞淋巴瘤反应性关系及预测价值  

The relationship between the levels of serum FOXO1 and Beclin-1 and the response to rituximab treatment in treatment-naїve patients diagnosed diffuse large B-cell lymphoma and its predictive value

作　　者：赵瑾[1] 于凤丽 关涛[1] 马莉[1] 郑美婧[1] 苏丽萍[1] Zhao Jin;Yu Fengli;Guan Tao;Ma li;Zheng Meijing;Su Liping(Department of Hematology,Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Shanxi 030013,China;Peking University People′s Hospital Shijiazhuang Hospital,Shijiazhuang 050000,China)

机构地区：[1]山西省肿瘤医院/中国医学科学院肿瘤医院山西医院/山西医科大学附属肿瘤医院血液内科,太原030013 [2]北京大学人民医院石家庄医院,石家庄050000

出　　处：《中华转移性肿瘤杂志》2024年第6期580-587,共8页Chinese Journal of Metastatic Cancer

基　　金：山西省科技厅基础研究计划项目(202203021222388)。

摘　　要：目的探讨血清叉头框蛋白O1(FOXO1)、自噬相关蛋白(Beclin-1)水平与利妥昔单抗治疗初诊弥漫大B细胞淋巴瘤(DLBCL)反应性关系及预测价值。方法选取2018年1月至2020年12月山西省肿瘤医院初诊DLBCL患者160例,分为训练组80例构建预测模型,验证组80例组外验证;同期健康志愿者80例为对照组。结果连续治疗4个周期后训练组血清FOXO1、Beclin-1水平高于治疗前,但均低于对照组(P<0.05);R-CHOP方案、R-CHOP样方案患者连续治疗4个周期后血清FOXO1、Beclin-1水平高于治疗前(P<0.05)。Ann Arbor分期、IPI评分、结外器官受累个数是利妥昔单抗治疗初诊DLBCL反应性的危险因素,治疗前血清FOXO1、Beclin-1水平是其保护因素(P<0.05)。治疗前血清FOXO1、Beclin-1水平加入多因素Logistic回归模型后可将预测利妥昔单抗治疗初诊DLBCL反应性的AUC值提升至0.892;组外验证显示回归模型预测利妥昔单抗治疗初诊DLBCL反应性的AUC值为0.918。结论血清FOXO1、Beclin-1水平是利妥昔单抗治疗初诊DLBCL反应性的独立影响因素,早期检测可为临床评估利妥昔单抗治疗初诊DLBCL反应性提供参考。Objective To investigate the relationship between serum levels of forkhead box protein O1(FOXO1)and autophagy-related protein(Beclin-1)and the response to rituximab treatment in treatment-naїve patients diagnosed diffuse large B-cell lymphoma(DLBCL),and to assess its predictive value.Methods A total of 160 treatment-naїve patients diagnosed DLBCL who were treated in Shanxi Province Cancer Hospital from January 2018 to December 2020 were divided into a training group(80 cases)to build a prediction model and a validation group(80 cases)for out-of-group validation.At the same time,80 healthy subjects were assigned to the control group.Results After four consecutive treatment cycles,the levels of FOXO1 and Beclin-1 in the training group were higher than those before treatment,but lower than those in the control group(P<0.05).In both of the R-CHOP and R-CHOP-like regimens,the serum levels of FOXO1 and Beclin-1 were higher after four consecutive treatment cycles compared to those before treatment(P<0.05).The Ann Arbor staging,IPI score,and number of extranodal organ involvement were risk factors for the response to rituximab in the treatment of DLBCL,while the levels of serum FOXO1 and Beclin-1 before treatment were protective factors(P<0.05).After adding serum FOXO1 and Beclin-1 levels before treatment to the multiple Logistic regression model,the AUC value for predicting the response of newly diagnosed DLBCL to rituximab treatment was increased to 0.892.Out-of-group validation showed that the regression model predicted an AUC value of 0.918 for initial DLBCL responsiveness to rituximab treatment.Conclusion The levels of serum FOXO1 and Beclin-1 are independent factors affecting the response of DLBCL to rituximab treatment,and early detection can provide a reference for clinical evaluation of the treatment response.

关 键 词：叉头框蛋白O1 自噬相关蛋白 利妥昔单抗 弥漫大B细胞淋巴瘤 初诊 

分 类 号：R73[医药卫生—肿瘤]